Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is positioned for success with their strong focus on genetic medicines, cutting-edge technology, and a promising pipeline led by their lead candidate PBFT02. They have a strong financial outlook with a conservative approach, reflected in their target price of $23 per share based on a sum-of-the-parts peak revenue analysis and a 12% discount rate.

Bears say

Passage Bio is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases, which poses typical upsides and downsides for a biotech company. Recently, the company faced safety issues and had to amend protocols for its lead programs, and competition in the industry may further delay trials or impact commercial potential. With cash overhang and potentially limited access to future financing, Passage Bio faces significant risks in progressing their pipeline and achieving regulatory approvals.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.